Efficacy and satisfaction analysis of biodegradable amniotic lacrimal duct repair stent for acquired lacrimal obstruction
4 affiliations
- 1Department of Ophthalmology, Peking University Third Hospital; Beijing Key Laboratory of Restoration of Damaged Ocular Nerve, Beijing 100191, China
- 2Department of Ophthalmology, Daping Hospital, Army Medical University, Chongqing 400010, China
- 3State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, Guangdong Province, China
- 4Department of Ophthalmology, Affiliated Hospital of Guizhou Medical University, Guiyang 550004, Guizhou Province, China
Abstract
AIM: To evaluate the efficacy, degradation characteristics, safety, and patient satisfaction of biodegradable amniotic lacrimal duct repair stent (ALDRS) in adult patients with acquired lacrimal obstruction. METHODS: A multicenter, retrospective cohort study. Patients were stratified by anatomical site and obstruction severity into three cohorts: incomplete upper lacrimal pathway obstruction (punctal, canalicular, or common canalicular, cohort 1), incomplete nasolacrimal duct obstruction (cohort 2), and complete nasolacrimal duct obstruction (cohort 3). The primary endpoint was anatomical patency on lacrimal irrigation at 6mo. Secondary endpoints included functional success, stent degradation, complications, and validated patient-reported outcomes. RESULTS: A total of 54 patients (54 eyes, 10 males) with a mean age of 53.36±12.42y (range 29–88) were enrolled. ALDRS insertion was successful in 98.15% of procedures. Complete degradation was observed in 90.74% of eyes at 30d and in 100% by 6mo, with no residual material. The overall anatomical patency rate at 6mo was 81.48%. By cohort, patency was 100% (11/11), 88.89% (16/18), and 68.00% (17/25) for cohort 1, 2, and 3, respectively. No granuloma, punctal laceration, or silicone tube related complications occurred. Pre-existing chronic dacryocystitis was an independent risk factor for reduced patency [B=0.607, 95% confidence interval (CI): 0.165–1.048, t=2.763, P=0.008]. Overall satisfaction was comparable among cohorts, with all patients ranking preoperative communication and explanation highest. CONCLUSION: Biodegradable ALDRS combines avoidance of secondary removal with promotion of epithelialization, offering a safe and patient friendly option for adult acquired lacrimal obstruction. Lacrimal probing with ALDRS achieves favorable outcomes in cohort 1 and 2. In cohort 3, ALDRS is best reserved as a prophylactic adjunct after dacryocystorhinostomy. Chronic dacryocystitis or severe lacrimal sac fibrosis compromises efficacy.
Related
- General self-efficacy, self-confidence, and satisfaction in simulation-based nursing education: a structural equation modeling and mediation analysis
- Efficacy of endoscopic ultrasound-guided versus surgical gastrojejunostomy for malignant gastric outlet obstruction: a systematic review and meta-analysis
- Digital transformation in nursing education: students’ satisfaction, academic self-efficacy, and challenges with interactive e-books
- Yiguanjian alleviates ocular surface inflammation and lacrimal gland immune dysregulation in experimental dry eye disease: evidence from in vivo and in vitro models
- Extension of a Severed Paul Glaucoma Implant Tube Using the Crawford Lacrimal Tube: A Novel Surgical Technique.
BibTeX
@article{zhao2026efficacy,
title = {{Efficacy and satisfaction analysis of biodegradable amniotic lacrimal duct repair stent for acquired lacrimal obstruction}},
author = {Tian-Yao Zhao and Hua Liu and Xiao-Ran Wang and Ping Xie and Yan-Jie Tian and Xue-Min Li},
journal = {International Journal of Ophthalmology},
year = {2026},
month = nov,
doi = {10.18240/ijo.2026.11.07},
url = {https://doi.org/10.18240/ijo.2026.11.07},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Efficacy and satisfaction analysis of biodegradable amniotic lacrimal duct repair stent for acquired lacrimal obstruction
AU - Tian-Yao Zhao
AU - Hua Liu
AU - Xiao-Ran Wang
AU - Ping Xie
AU - Yan-Jie Tian
AU - Xue-Min Li
PY - 2026
DA - 2026/11/02
JO - International Journal of Ophthalmology
DO - 10.18240/ijo.2026.11.07
UR - https://doi.org/10.18240/ijo.2026.11.07
AB - AIM: To evaluate the efficacy, degradation characteristics, safety, and patient satisfaction of biodegradable amniotic lacrimal duct repair stent (ALDRS) in adult patients with acquired lacrimal obstruction. METHODS: A multicenter, retrospective cohort study. Patients were stratified by anatomical site and obstruction severity into three cohorts: incomplete upper lacrimal pathway obstruction (punctal, canalicular, or common canalicular, cohort 1), incomplete nasolacrimal duct obstruction (cohort 2), and complete nasolacrimal duct obstruction (cohort 3). The primary endpoint was anatomical patency on lacrimal irrigation at 6mo. Secondary endpoints included functional success, stent degradation, complications, and validated patient-reported outcomes. RESULTS: A total of 54 patients (54 eyes, 10 males) with a mean age of 53.36±12.42y (range 29–88) were enrolled. ALDRS insertion was successful in 98.15% of procedures. Complete degradation was observed in 90.74% of eyes at 30d and in 100% by 6mo, with no residual material. The overall anatomical patency rate at 6mo was 81.48%. By cohort, patency was 100% (11/11), 88.89% (16/18), and 68.00% (17/25) for cohort 1, 2, and 3, respectively. No granuloma, punctal laceration, or silicone tube related complications occurred. Pre-existing chronic dacryocystitis was an independent risk factor for reduced patency [B=0.607, 95% confidence interval (CI): 0.165–1.048, t=2.763, P=0.008]. Overall satisfaction was comparable among cohorts, with all patients ranking preoperative communication and explanation highest. CONCLUSION: Biodegradable ALDRS combines avoidance of secondary removal with promotion of epithelialization, offering a safe and patient friendly option for adult acquired lacrimal obstruction. Lacrimal probing with ALDRS achieves favorable outcomes in cohort 1 and 2. In cohort 3, ALDRS is best reserved as a prophylactic adjunct after dacryocystorhinostomy. Chronic dacryocystitis or severe lacrimal sac fibrosis compromises efficacy.
SN - 2222-3959
SN - 2227-4898
ER -